FRIMLEY, England, June 2 /PRNewswire/ --

- Randomised Phase II data show RAD001 significantly increased efficacy of letrozole in women with newly diagnosed hormone-positive breast cancer - Phase I studies suggest RAD001 may help overcome a major pathway of resistance to trastuzumab - Novartis to further explore potential of RAD001 in breast cancer by initiating new trial in early 2009

Early proof-of-concept studies presented today show RAD001 (everolimus) may offer a novel treatment strategy for breast cancer by enhancing the efficacy of, and overcoming resistance to, several commonly used breast cancer treatments.

Findings from a Phase II study show that RAD001 enhances tumour shrinkage when given in combination with letrozole (Femara(R)) to postmenopausal women with newly diagnosed oestrogen receptor-positive (ER+) breast cancer. Further, initial results from two Phase I trials in which RAD001 was combined with trastuzumab (Herceptin(R)) and chemotherapy agents suggest that the addition of RAD001 overcame resistance to trastuzumab. The combination appears highly active, achieving complete responses in a few patients and partial responses or stable disease in a majority of patients.

These results were among several studies of RAD001 presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, US. Findings of a Phase III trial in metastatic renal cell carcinoma showing that RAD001 more than doubled the time without tumour growth after failure of standard treatments were presented earlier in the meeting. RAD001 is an investigational once-daily oral therapy that may offer a new approach to cancer treatment by continuously inhibiting the mTOR protein, a central regulator of tumour cell division and blood vessel growth in cancer cells.

"These findings show potential to improve outcomes for early-stage, hormone-sensitive breast cancer patients by adding RAD001 to initial treatment with letrozole," said Dr Peter Harper, Consultant Medical Oncologist, Guy's and St Thomas'. "Taken together, the results from all of these trials further underscore RAD001's promise across various subsets of breast cancers, as well as other tumours, including advanced kidney cancer."

For breast cancer patients whose disease becomes resistant to available drugs, identifying the mechanism of resistance is important for restoring activity to treatment. Preclinical studies have shown that RAD001, an inhibitor of mTOR, acts on the pathway that mediates trastuzumab resistance and has the potential to help restore response in patients who are refractory to therapy. RAD001 works through direct antitumour activity as well as through its influence on two of the most important pathways for breast cancer, the oestrogen receptor and the HER2/neu pathways.

Based on these data, Novartis will initiate a new trial to evaluate the potential of RAD001 in breast cancer in early 2009. Plans for this trial are ongoing and will be announced at a later date.

Notes to Editors

Study results

ABSTRACT #530 - "Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomised phase II neoadjuvant trial in ER+ breast cancer"

Jose Baselga, MD, Hospital Vall D'Hebron, Barcelona, Spain

This randomised, double-blind, Phase II placebo-controlled trial of 270 postmenopausal women found that RAD001 10 mg significantly increased both the clinical and the cell cycle efficacy of letrozole 2.5 mg in the treatment of newly diagnosed ER+ breast cancer. The overall clinical response rate with RAD001 in combination with letrozole was significantly superior to letrozole alone (68% versus 59%, one-sided P=0.062, respectively). The results were also confirmed by ultrasound (58% versus 47%, one-sided P=0.035, respectively). In addition, cell cycle response in the RAD001/letrozole treatment arm, as measured by major reduction in Ki67, an indication of tumour cell proliferation, was twice that as measured in the placebo/letrozole treatment arm.

Adverse events in the RAD001/letrozole treatment arm were manageable. The most frequent grade 3/4 adverse events in the RAD001/letrozole treatment arm were high blood sugar (5%), mouth sores (2%), pneumonitis (2%) and infections (2%). The rate of grade 3/4 adverse events was 23% in the RAD001/letrozole treatment arm versus 4% in the placebo/letrozole treatment arm. All three cases of grade 3 pneumonitis completely resolved after discontinuation of RAD001.

ABSTRACT #1003 - "Multicentre phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab"

Fabrice Andre, MD, PhD, Institut Gustave Roussy, Villejuif, France

This multicentre Phase I-II trial evaluated daily RAD001 (5 mg, 10 mg) and weekly RAD001 (30 mg, 50 mg and 70 mg) regimens in combination with paclitaxel (80 mg/m2, IV over 60 min on days 1, 8 and 15 q4w) and trastuzumab (4 mg/kg loading dose, IV over 90 min on day 1 [if patient was not already receiving trastuzumab], followed by weekly 2 mg/kg IV over 30 min) in heavily pretreated patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Thirteen heavily pretreated patients were assessable for efficacy to date: treatment arms included five patients assigned to RAD001 5 mg daily, one to 10 mg daily and seven to 30 mg weekly. Among the five patients allocated to the 5 mg daily arm, four patients had confirmed partial responses (including three complete responses, yet to be confirmed); the one patient on 10 mg daily showed stable disease at the first assessment; and of the seven patients evaluated in the RAD001 weekly treatment arm, two patients had confirmed partial response and four patients had long disease stabilisation, including complete disappearance of brain metastasis in one patient. The most commonly reported adverse events were neutropenia and mouth sores.

"These preliminary results are very exciting given that the women in the study were heavily pretreated, had documented resistance to trastuzumab and most were also taxane-resistant," said Fabrice Andre, MD, PhD, Institut Gustave Roussy, Villejuif, France. "If confirmed in Phase II and III clinical trials, RAD001 will be a major addition to the existing arsenal of breast cancer therapy."

ABSTRACT #1057 - "Multicentre phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab"

Guy H. Jerusalem, MD, Sart-Tilman, Liege, Belgium

This multicentre Phase I trial evaluated daily RAD001 (5 mg, 10 mg) and weekly RAD001 (20 mg, 30 mg, 50 mg and 70 mg) regimens. Patients were administered vinorelbine (25 mg/m2, IV over 10-15 min on days 1 and 8 q3w) and trastuzumab (4 mg/kg loading dose, IV over 90 min on day 1 [if patient was not already receiving trastuzumab], followed by weekly trastuzumab 2 mg/kg IV over 30 min). Twenty-two heavily pretreated patients were evaluated for efficacy to date: 11 allocated to RAD001 5 mg daily, six to RAD001 20 mg weekly and five to RAD001 30 mg weekly treatment arms. All patients entering the study had progression on or shortly after treatment with trastuzumab and all had received prior taxane. The median number of prior chemotherapy regimens was 3 (range: 1-5). A preliminary efficacy analysis in the 11 patients enrolled in the RAD001 5 mg treatment arm showed that one patient had a confirmed complete response (35+ weeks), one patient had a confirmed partial response (29+ weeks) and six patients had stable disease (9+, 12, 17+, 18+, 29, 39 weeks). Grade 2 and 3 mouth sores and grade 3 and 4 neutropenia were seen. Among 11 patients evaluated for preliminary efficacy in the RAD001 weekly arms, one had partial response (29+ weeks) and seven had stable disease (16+, 17+, 19, 27, 35+, 46+, 53+ weeks). Similar to the daily arm, grade 2 and 3 mouth sores and grade 3 and 4 neutropenia were seen.

About breast cancer

Breast cancer is the most common cancer in the UK with more than 44,000 cases diagnosed in women every year and the second most common cancer-related cause of death in women (after lung cancer). According to Cancer Research UK, each year approximately 12,000 UK women die from the disease. Moreover, the incidence of breast cancer in the UK has risen by 12% in the last ten years.

Inside a breast there are many lobes, ducts and vessels that support several important functions in the body, including reproductive needs and fighting infection. In breast cancer, some of the cells in the breast begin growing abnormally and divide more rapidly than healthy cells. The quick division of cells may cause spreading through the breast, to the lymph nodes or to other parts of the body.

About RAD001

RAD001, an oral inhibitor of mTOR, is an investigational drug being studied in multiple tumour types. In cancer cells, RAD001 inhibits mTOR, a protein that acts as a central regulator of tumour cell division, cell metabolism and blood vessel growth. RAD001 is a once-daily oral therapy that provides continuous inhibition of mTOR.

In addition to breast cancer, RAD001 is presently being evaluated in renal cell carcinoma; neuroendocrine tumours; lymphoma, lung, stomach and liver cancers, in addition to other cancers; and in tuberous sclerosis complex as a single agent or in combination with existing cancer therapies.

As an investigational compound, the safety and efficacy profile of RAD001 has not yet been established in oncology. Access to RAD001 is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of clinical trials, there is no guarantee that RAD001 will ever be commercially available for oncology indications anywhere in the world.

About Femara

Femara is a leading once-daily oral aromatase inhibitor available in more than 90 countries, including the US, UK, major European markets, and Japan. Femara is approved for:

- Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer - Extended adjuvant treatment of hormone-dependent early breast cancer in postmenopausal women who have had prior standard adjuvant tamoxifen therapy for five years - First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer - Advanced breast cancer in women with natural or artificially induced postmenopausal status after relapse or disease progression who have been treated with anti-oestrogens - Pre-operative therapy in postmenopausal women with localised hormone receptor-positive breast cancer which allows subsequent breast-conserving surgery in patients not originally considered suitable for this type of surgery - Subsequent treatment after surgery should be in accordance with standard of care. Not all indications are available in every country.

Femara should not be taken by women who have previously had any unusual or allergic reactions to letrozole or any of its ingredients. Femara should not be taken by women who are pregnant or breastfeeding. Only women who are postmenopausal should take Femara. Patients with severe liver impairment should be monitored closely. The use of Femara in patients with significantly impaired kidney function warrants careful consideration.

The most common side effects of Femara are hot flushes, fatigue, joint pain and nausea. Other common side effects are anorexia, appetite increase, peripheral oedema, headache, dizziness, vomiting, dyspepsia, constipation, diarrhoea, hair loss, increased sweating, rash, muscle pain, bone pain, arthritis, osteoporosis, bone fractures, weight increase, hypercholesterolaemia and depression. Other rare, but potentially serious adverse events include leukopaenia, cataracts, cerebrovascular accident or infarction, thrombophlebitis, pulmonary embolism, arterial thrombosis and ischemic cardiovascular disease.

About Novartis

Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit

For more information, please contact: Fiona Turner, Novartis Pharmaceuticals UK Ltd, Tel: +44(0)1276-698086, Fax: +44(0)1276-698605, E:; Charlotte Binstead, Red Health, Tel: +44(0)207-025-6592, Fax: +44(0)207-025-6499, E: